TickerFacts.

Metagenomi Therapeutics, Inc. (MGX): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$89.47M
Year ended 2025-12-31
-$85.80M
Trailing 12 months to 2026-06-30
2023-12-31: -$101.22M2024-12-31: -$112.19M2025-12-31: -$89.47M-$89.47M
2023-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$89.47Mn/m2026-03-05, From 2025-01-01
2024-12-31-$112.19Mn/m2026-03-05, From 2024-01-01
2023-12-31-$101.22Mn/a2025-03-17, From 2023-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Metagenomi Therapeutics, Inc. (MGX)2025-12-31-$89.47Mn/m
Alector, Inc. (ALEC)2025-12-31-$184.07Mn/m
Scilex Holding Co (SCLX)2025-12-31$3.68M-81.0%
LENZ Therapeutics, Inc. (LENZ)2025-12-31-$70.00Mn/m
Precision Biosciences Inc (DTIL)2025-12-31-$65.93Mn/m
X4 Pharmaceuticals, Inc (XFOR)2025-12-31-$85.62Mn/m
C4 Therapeutics, Inc. (CCCC)2025-12-31-$99.30Mn/m
Pelthos Therapeutics Inc. (PTHS)2025-12-31-$22.69Mn/m
Kymera Therapeutics, Inc. (KYMR)2025-12-31-$234.34Mn/m

Compare MGX, ALEC, SCLX, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗